Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGSWW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GeneDx Holdings Corp. filings document the regulatory record for a genomics diagnostics company focused on pediatric and rare disease testing, including whole exome and genome sequencing. Form 8-K reports include quarterly and annual financial results, earnings presentation exhibits, statement presentation changes, non-GAAP measure methodology, and material financing agreements.
The company's disclosures also cover its capital structure, including Class A common stock and Nasdaq-listed warrants under WGSWW. Proxy materials address executive compensation, equity awards, shareholder voting matters, and other governance items, while debt filings describe term-loan arrangements, guarantor subsidiaries, use of proceeds, repayment obligations, and default provisions.
GeneDx Holdings Corp. files its annual report describing a genomics business built around exome and whole genome sequencing, including ExomeDx™ and GenomeDx™ tests that hold FDA Breakthrough Device Designation. The company emphasizes one of the world’s largest rare disease datasets, with over 2.5 million tests, including more than 1 million exomes and genomes, and a high proportion of non‑European samples.
Growth priorities focus on pediatric outpatient genetics, NICU rapid genomes, prenatal testing and genomic newborn screening through studies such as GUARDIAN, BEACONS and SeqFirst, plus international expansion via the 2025 Fabric Genomics acquisition. The report details a heavily regulated environment, reimbursement dependence, intense competition, extensive use of AI for interpretation, and broad U.S. and international privacy, laboratory, and fraud‑and‑abuse compliance obligations.
GeneDx Holdings Corp. files its annual report describing a genomics business built around exome and whole genome sequencing, including ExomeDx™ and GenomeDx™ tests that hold FDA Breakthrough Device Designation. The company emphasizes one of the world’s largest rare disease datasets, with over 2.5 million tests, including more than 1 million exomes and genomes, and a high proportion of non‑European samples.
Growth priorities focus on pediatric outpatient genetics, NICU rapid genomes, prenatal testing and genomic newborn screening through studies such as GUARDIAN, BEACONS and SeqFirst, plus international expansion via the 2025 Fabric Genomics acquisition. The report details a heavily regulated environment, reimbursement dependence, intense competition, extensive use of AI for interpretation, and broad U.S. and international privacy, laboratory, and fraud‑and‑abuse compliance obligations.
GeneDx Holdings Corp. reported strong growth for 2025, with revenue rising to $427.5 million, up 41% year over year, and exome and genome test revenue reaching $360.3 million, up 54%. Adjusted gross margin improved to 71% and adjusted net income increased to $41.8 million from $9.4 million in 2024, while GAAP net loss narrowed to $21.0 million.
Fourth-quarter 2025 revenue was $121.0 million, including $104.0 million from exome and genome testing, with test volumes up 34.3% to 27,761. The company ended the year with $172.3 million in cash, cash equivalents, marketable securities and restricted cash and reaffirmed 2026 guidance for revenue of $540–$555 million, 33–35% exome and genome growth, adjusted gross margin of at least 70%, and positive adjusted net income.
GeneDx Holdings Corp. reported strong growth for 2025, with revenue rising to $427.5 million, up 41% year over year, and exome and genome test revenue reaching $360.3 million, up 54%. Adjusted gross margin improved to 71% and adjusted net income increased to $41.8 million from $9.4 million in 2024, while GAAP net loss narrowed to $21.0 million.
Fourth-quarter 2025 revenue was $121.0 million, including $104.0 million from exome and genome testing, with test volumes up 34.3% to 27,761. The company ended the year with $172.3 million in cash, cash equivalents, marketable securities and restricted cash and reaffirmed 2026 guidance for revenue of $540–$555 million, 33–35% exome and genome growth, adjusted gross margin of at least 70%, and positive adjusted net income.
GeneDx Holdings Corp. Chief Operating Officer Bryan Dechairo reported RSU vesting and related share sales. On February 1, 2026, 9,374 restricted stock units converted into an equal number of Class A Common shares at $0 per share upon vesting. On February 2, 2026, he sold a total of 3,413 shares in multiple transactions at weighted average prices between $96.7676 and $100.3146 per share to cover tax withholding obligations under a “sell to cover” arrangement, described as non-discretionary. Following these transactions, he directly beneficially owned 5,961 shares of Class A Common Stock and RSUs representing contingent rights to receive up to 28,123 additional shares, vesting over time subject to continued service.
GeneDx Holdings Corp. Chief Operating Officer Bryan Dechairo reported RSU vesting and related share sales. On February 1, 2026, 9,374 restricted stock units converted into an equal number of Class A Common shares at $0 per share upon vesting. On February 2, 2026, he sold a total of 3,413 shares in multiple transactions at weighted average prices between $96.7676 and $100.3146 per share to cover tax withholding obligations under a “sell to cover” arrangement, described as non-discretionary. Following these transactions, he directly beneficially owned 5,961 shares of Class A Common Stock and RSUs representing contingent rights to receive up to 28,123 additional shares, vesting over time subject to continued service.
A holder of WGS Class A common stock filed a notice of intent to sell 9,374 shares under Rule 144. The shares have an aggregate market value of 929900 and are part of 28,904,590 shares outstanding. The planned sale date is approximately 02/02/2026 on NASDAQ through Morgan Stanley Smith Barney.
The seller acquired the 9,374 shares of Class A common stock on 01/14/2025 as compensation in the form of restricted stock units from the issuer, with compensation as the nature of payment. The signer represents they are not aware of undisclosed material adverse information about the issuer’s operations.
A holder of WGS Class A common stock filed a notice of intent to sell 9,374 shares under Rule 144. The shares have an aggregate market value of 929900 and are part of 28,904,590 shares outstanding. The planned sale date is approximately 02/02/2026 on NASDAQ through Morgan Stanley Smith Barney.
The seller acquired the 9,374 shares of Class A common stock on 01/14/2025 as compensation in the form of restricted stock units from the issuer, with compensation as the nature of payment. The signer represents they are not aware of undisclosed material adverse information about the issuer’s operations.
GeneDx Holdings Corp. chief financial officer Kevin Feeley reported routine equity compensation activity involving restricted stock units (RSUs) and related share sales. On January 29, 2026, 754 RSUs converted into the same number of Class A Common shares for no cash consideration.
On the same date, Feeley sold 315 shares at $94 and 2 shares at $92.0601. The company states these sales were made solely to cover tax withholding obligations through a “sell to cover” arrangement and were not discretionary trades. After these transactions, Feeley directly held 9,168 Class A Common shares, plus RSUs representing up to 112,750 shares and options for up to 25,906 shares, all vesting according to their existing schedules.
GeneDx Holdings Corp. chief financial officer Kevin Feeley reported routine equity compensation activity involving restricted stock units (RSUs) and related share sales. On January 29, 2026, 754 RSUs converted into the same number of Class A Common shares for no cash consideration.
On the same date, Feeley sold 315 shares at $94 and 2 shares at $92.0601. The company states these sales were made solely to cover tax withholding obligations through a “sell to cover” arrangement and were not discretionary trades. After these transactions, Feeley directly held 9,168 Class A Common shares, plus RSUs representing up to 112,750 shares and options for up to 25,906 shares, all vesting according to their existing schedules.
GeneDx Holdings Corp.'s chief executive officer Katherine Stueland reported routine equity activity tied to restricted stock units. On January 29, 2026 she settled 3,874 RSUs into the same number of Class A common shares for no cash cost, then sold 1,653 shares at a weighted average price of $93.9957 to cover tax withholding obligations through a non‑discretionary “sell to cover” transaction. After these moves she directly owned 16,458 Class A shares, along with RSUs representing contingent rights to receive up to 411,494 additional shares and options to purchase up to 107,610 shares, which vest according to their existing schedules.
GeneDx Holdings Corp.'s chief executive officer Katherine Stueland reported routine equity activity tied to restricted stock units. On January 29, 2026 she settled 3,874 RSUs into the same number of Class A common shares for no cash cost, then sold 1,653 shares at a weighted average price of $93.9957 to cover tax withholding obligations through a non‑discretionary “sell to cover” transaction. After these moves she directly owned 16,458 Class A shares, along with RSUs representing contingent rights to receive up to 411,494 additional shares and options to purchase up to 107,610 shares, which vest according to their existing schedules.
A Form 144 notice shows a planned insider sale of 24,155 shares of Class A common stock, with an aggregate market value of $2,369,700. The shares are expected to be sold on or about 01/29/2026 on NASDAQ through Morgan Stanley Smith Barney.
The securities were acquired as compensation in the form of restricted stock units and performance-based restricted stock units on several dates between 2022 and 2025. The document also lists recent sales by Kevin Feeley over the past three months, including blocks such as 3,855 shares on 12/16/2025 for gross proceeds of $554,632.
WGS insider Katherine Stueland has filed a notice of proposed sale of 94,495 shares of Class A common stock through broker Morgan Stanley Smith Barney on NASDAQ. The filing lists an aggregate market value of 9268700 for these shares and shows 28,904,590 shares of this class outstanding.
The shares to be sold were acquired as equity compensation, including restricted stock units and performance-based restricted stock units granted between 2022 and 2025. The notice also reports prior sales over the last three months, including 2,158, 3,639, and 10,857 shares of Class A common stock, with stated gross proceeds for each transaction.
Thomas Fuchs, a director of GeneDx Holdings Corp. (ticker shown as WGS), was granted 3,438 restricted stock units (RSUs) on 09/17/2025. Each RSU converts into one share of Class A Common Stock for no consideration when settled. The award vests in three equal installments on 09/17/2026, 09/17/2027, and 09/17/2028, subject to the reporting persons continued service. Following the grant, the reporting person beneficially owns 3,438 shares of Class A Common Stock as a direct owner. The Form 4 was signed by an attorney-in-fact on 09/19/2025.
Thomas Fuchs filed an initial Form 3 reporting his relationship to GeneDx Holdings Corp. (ticker: WGS) as a Director. The event date triggering the filing is 09/17/2025. The form states that no securities are beneficially owned by the reporting person. The filing is signed on behalf of Mr. Fuchs by Bridget Brown, Attorney-in-Fact dated 09/19/2025.